Latest Tykerb Stories
A combination of two targeted therapies already shown to be effective in breast cancer packs an effective one-two punch against a subset of gastric cancers that have a specific genetic mutation
WALTHAM, Mass., Feb.
PHILADELPHIA, Jan. 29 /PRNewswire/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S.
Provides oral regime for hormone positive and HER2-positive advanced breast cancer SILVER SPRING, Md., Jan. 29 /PRNewswire-USNewswire/ -- The U.S.
LONDON and PHILADELPHIA, Dec. 11 /PRNewswire/ -- In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERBÂ® (lapatinib) plus HERCEPTINÂ® (trastuzumab).
NEW YORK, Sept.
GlaxoSmithKline PLC has petitioned the United States and Europe for permission in to market an already accessible breast-cancer drug as a first-line treatment option.
LONDON and PHILADELPHIA, April 1, /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced the submission of two simultaneous regulatory applications to expand the use of TYVERB(R)/TYKERB(R) (lapatinib).
By Lisa Richwine ATLANTA (Reuters) - An experimental drug added to chemotherapy slowed aggressive, late-stage breast cancers that resumed growing despite standard treatment with the drug Herceptin, U.S. researchers said on Saturday.